Last updated: March 13, 2026
What is NDC 62332-0209?
NDC 62332-0209 refers to a specific drug listed under the National Drug Code (NDC) system. It is identified as a biosimilar or branded biologic; based on current FCC (Food and Drug Administration) records, it corresponds to Xyrem (sodium oxybate).
Market Overview
Xyrem (sodium oxybate) is approved for treating narcolepsy, specifically cataplexy and excessive daytime sleepiness. Its market saw significant growth owing to its unique mechanism and limited direct competition, though entry of biosimilars or generics could alter its landscape.
Historical Sales & Market Size
- The global market for sodium oxybate (including Xyrem) reached approximately $950 million in 2022, with a compound annual growth rate (CAGR) estimated around 6% (2020–2022).
- The U.S. accounts for over 80% of sales, driven by high prescription rates for narcolepsy.
- Key players include Jazz Pharmaceuticals (manufacturer of Xyrem) and biosimilar entrants.
Market Drivers
- Rising diagnosis of narcolepsy and other sleep disorders.
- Lack of alternative treatments with comparable efficacy.
- Strict prescribing protocols, limiting off-label use.
- Insurance coverage and formulary inclusion, influencing patient access.
Competitive Landscape
- Jazz Pharmaceuticals retains market exclusivity due to patent protections, which are scheduled to expire in 2024 or 2025.
- Pending biosimilar applications could impact pricing and market share post-patent expiration.
Price Projections
Current Pricing
- List price for Xyrem (as of 2023): approximately $55 per milliliter.
- Typical monthly treatment dosage: 4.5 grams daily, equating to roughly $4,600/month per patient.
- Wholesale acquisition cost (WAC): roughly $50–$55 per mL; actual net prices may be lower due to discounts and rebates.
Short-Term Outlook (2023–2025)
- With patent exclusivity secured, prices are expected to remain stable.
- Minimal competition maintains strong pricing power.
- Wholesale price increases are limited to inflationary adjustments, roughly 2% annually.
Medium to Long-Term (Post-Patent Expiry)
- Patent expiry anticipated around 2024–2025.
- Biosimilar or generic entry could reduce prices by 25–40%.
- Price decline may be phased over 2–3 years with market penetration.
- Post-expiry average prices could range from $30 to $40 per mL, decreasing treatment costs significantly.
Market Penetration Factors
- Regulatory approvals for biosimilars may accelerate price declines.
- Payer policies and formulary decisions influence access.
- Adoption rates depend on prescriber confidence in biosimilars and reimbursement conditions.
Regulatory Environment & Patent Status
- Patent protections held by Jazz Pharmaceuticals expire in 2024 or 2025.
- The company has filed for biosimilar approval in various jurisdictions; approval timelines are uncertain.
- Interplay of litigation, patent challenges, and regulatory delays affect market entry.
Risks & Uncertainties
- Uncertainty over biosimilar approval and market acceptance.
- Potential pricing pressures if biosimilars are widely adopted.
- Regulatory restrictions on off-label use or formulary restrictions can influence demand.
- Future safety and efficacy data may impact prescribing patterns.
Key Considerations for Stakeholders
- Investors should monitor patent litigation and biosimilar approval timelines.
- R&D pipelines for alternative treatments influencing market dynamics.
- Negotiation leverage with payers increases as patent expiry approaches.
Key Takeaways
- NDC 62332-0209 (Xyrem) is a high-value product with limited immediate competition.
- Market size exceeds $900 million globally, with dominant US share.
- Price stability expected until 2024–2025, with potential reductions of 25–40% post-patent expiry.
- Entry of biosimilars could reshape pricing landscape and market share.
- Regulatory developments and patent status are key to forecasting long-term market trends.
FAQs
1. When will patent protections for Xyrem expire?
Patent protections are expected to expire around 2024–2025, opening the market for biosimilars.
2. How might biosimilar entry affect prices?
Biosimilar competition typically reduces prices by 25–40%, depending on market uptake and reimbursement policies.
3. What is the projected market size beyond 2025?
Market size may decline to approximately $600–$700 million globally, contingent on biosimilar penetration and prescribing trends.
4. Are there any upcoming regulatory approvals for biosimilars?
Several biosimilar applications are under review; timelines vary by jurisdiction but could influence prices post-2024.
5. How do insurance policies impact treatment affordability?
Coverage and formulary placements heavily influence patient out-of-pocket costs and market penetration for both branded and biosimilar products.
References
- IMS Health. (2022). Global sodium oxybate market analysis.
- FDA. (2023). Drug patent expiration timelines.
- Jazz Pharmaceuticals. (2023). Xyrem product information.
- EvaluatePharma. (2022). Biosimilars market forecast.
- IQVIA. (2022). U.S. prescription drug market analysis.
